Details for Patent: 8,425,934

« Back to Dashboard

Which drugs does patent 8,425,934 protect, and when does it expire?

Patent 8,425,934 protects BRILINTA and is included in one NDA.

Protection for BRILINTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in thirty-four countries.

Summary for Patent: 8,425,934

Title:	Pharmaceutical compositions
Abstract:	The present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1α,2α,3β(1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.
Inventor(s):	Simon Banks
Assignee:	AstraZeneca AB
Application Number:	US11/841,030
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,425,934
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,425,934

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	BRILINTA	ticagrelor	TABLET;ORAL	022433-002	Sep 3, 2015	AB	RX	Yes	No	8,425,934*PED				Y
Astrazeneca	BRILINTA	ticagrelor	TABLET;ORAL	022433-001	Jul 20, 2011	AB	RX	Yes	Yes	8,425,934*PED				Y

International Family Members for US Patent 8,425,934

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	062451
Australia	2007288541
Australia	2011205164
Brazil	PI0715712